|
|
|
|
|
|
|
|
|
|
|
TB case notifications 2014
|
New **
|
Relapse
|
Pulmonary, bacteriologically confirmed
|
7 874
|
|
1 899
|
Pulmonary, clinically diagnosed
|
2 421
|
|
356
|
Extrapulmonary
|
2 209
|
|
102
|
|
|
|
|
Total new and relapse
|
14 861
|
|
|
Previously treated, excluding relapses
|
1 045
|
|
|
Total cases notified
|
15 906
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Among 14 861 new and relapse cases:
|
|
|
|
|
|
|
639 (4%) cases aged under 15 years; male:female ratio: 2.1
|
|
|
|
|
|
|
|
|
|
|
|
|
Reported cases of RR-/MDR-TB 2014
|
New
|
Retreatment
|
Total **
|
Cases tested for RR-/MDR-TB
|
5 751 (73%)
|
2 171 (64%)
|
7 922
|
Laboratory-confirmed RR-/MDR-TB cases
|
|
|
578
|
Patients started on MDR-TB treatment ***
|
|
|
648
|
|
|
|
|
|
|
|
|
|
|
|
TB/HIV 2014
|
Number
|
(%)
|
TB patients with known HIV status
|
10 927
|
(69)
|
HIV-positive TB patients
|
312
|
(3)
|
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)
|
281
|
(90)
|
HIV-positive TB patients on antiretroviral therapy (ART)
|
278
|
(89)
|
HIV-positive people screened for TB
|
316
|
|
HIV-positive people provided with IPT
|
158
|
|
|
|
|
|
|
|
|
|
|
|
|
Treatment success rate and cohort size
|
(%)
|
Cohort
|
New and relapse cases registered in 2013
|
(85)
|
15 188
|
Previously treated cases, excluding relapse, registered in 2013
|
(45)
|
925
|
HIV-positive TB cases, all types, registered in 2013
|
(58)
|
250
|
RR-/MDR-TB cases started on second-line treatment in 2012
|
(34)
|
638
|
XDR-TB cases started on second-line treatment in 2012
|
(7)
|
41
|
|
|
|
|
|
|
|
|
|
|
|
Laboratories 2014
|
|
Smear (per 100 000 population)
|
0.5
|
Culture (per 5 million population)
|
23.2
|
Drug susceptibility testing (per 5 million population)
|
11.2
|
Sites performing Xpert MTB/RIF
|
3
|
Is second-line drug susceptibility testing available?
|
Yes, in country
|
|
|
|
|
|
|
|
|
|
|
|
Financing TB control 2015
|
|
National TB programme budget (US$ millions)
|
18
|
% Funded domestically
|
15%
|
% Funded internationally
|
67%
|
% Unfunded
|
18%
|
|
|
|
|
|
|
|
|
|
|
|
* Ranges represent uncertainty intervals
|
|
|
|
|
|
** Includes cases with unknown previous TB treatment history
|
|
|
|
*** Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having
|
|
RR-/MDR-TB
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|